Intercellular Lipid Mediators and GPCR Drug Discovery.
- Author:
Dong Soon IM
1
Author Information
1. Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea. imds@pusan.ac.kr
- Publication Type:Review
- Keywords:
Lipid mediator;
GPCR;
Lipid;
Lysophospholipid;
Fatty acid;
Drug discovery
- MeSH:
Drug Discovery*;
Fatty Acids, Nonesterified;
Homeostasis;
Ligands;
Lysophosphatidylcholines;
Lysophospholipids;
Receptors, G-Protein-Coupled;
Sphingosine;
Fingolimod Hydrochloride
- From:Biomolecules & Therapeutics
2013;21(6):411-422
- CountryRepublic of Korea
- Language:English
-
Abstract:
G-protein-coupled receptors (GPCR) are the largest superfamily of receptors responsible for signaling between cells and tissues, and because they play important physiological roles in homeostasis, they are major drug targets. New technologies have been developed for the identification of new ligands, new GPCR functions, and for drug discovery purposes. In particular, intercellular lipid mediators, such as, lysophosphatidic acid and sphingosine 1-phosphate have attracted much attention for drug discovery and this has resulted in the development of fingolimod (FTY-720) and AM095. The discovery of new intercellular lipid mediators and their GPCRs are discussed from the perspective of drug development. Lipid GPCRs for lysophospholipids, including lysophosphatidylserine, lysophosphatidylinositol, lysophosphatidylcholine, free fatty acids, fatty acid derivatives, and other lipid mediators are reviewed.
